Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis.
Ratsimandresy RA, Doran E, Dengler HS, Headland SE, Wedeles CJ, Guidi R, Xu D, Liu J, Shi Y, Wang J, Uttarwar S, Abbas AR, Sun T, DePianto DJ, Morshead KB, Arron J, Rock JR, Bevers J, Yadav R, Ramalingam T, Gao X, Brightbill HD, Emson CL, Jeet S, Arlantico A, Wong A, Yu S, Tran TH, Leong L, Dohse M, Austin C, Caplazi P, Panettieri RA, Koziol-White C, Jester WF, Shaw A, Avraham S, Menon H, Darmanis S, Modrusan Z, Kajihara K, Kanamori M, Shimada H, West NR, Nakamura G, Vander Heiden JA, Wilson MS.
Ratsimandresy RA, et al. Among authors: rock jr.
bioRxiv [Preprint]. 2026 Jan 13:2025.12.25.695625. doi: 10.64898/2025.12.25.695625.
bioRxiv. 2026.
PMID: 41497665
Free PMC article.
Preprint.